Unknown

Dataset Information

0

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.


ABSTRACT: Melanoma resistant to MAPK inhibitors (MAPKi) displays loss of fitness upon experimental MAPKi withdrawal and, clinically, may be resensitized to MAPKi therapy after a drug holiday. Here, we uncovered and therapeutically exploited the mechanisms of MAPKi addiction in MAPKi-resistant BRAFMUT or NRASMUT melanoma. MAPKi-addiction phenotypes evident upon drug withdrawal spanned transient cell-cycle slowdown to cell-death responses, the latter of which required a robust phosphorylated ERK (pERK) rebound. Generally, drug withdrawal-induced pERK rebound upregulated p38-FRA1-JUNB-CDKN1A and downregulated proliferation, but only a robust pERK rebound resulted in DNA damage and parthanatos-related cell death. Importantly, pharmacologically impairing DNA damage repair during MAPKi withdrawal augmented MAPKi addiction across the board by converting a cell-cycle deceleration to a caspase-dependent cell-death response or by furthering parthanatos-related cell death. Specifically in MEKi-resistant NRASMUT or atypical BRAFMUT melanoma, treatment with a type I RAF inhibitor intensified pERK rebound elicited by MEKi withdrawal, thereby promoting a cell death-predominant MAPKi-addiction phenotype. Thus, MAPKi discontinuation upon disease progression should be coupled with specific strategies that augment MAPKi addiction.Significance: Discontinuing targeted therapy may select against drug-resistant tumor clones, but drug-addiction mechanisms are ill-defined. Using melanoma resistant to but withdrawn from MAPKi, we defined a synthetic lethality between supraphysiologic levels of pERK and DNA damage. Actively promoting this synthetic lethality could rationalize sequential/rotational regimens that address evolving vulnerabilities. Cancer Discov; 8(1); 74-93. ©2017 AACR.See related commentary by Stern, p. 20This article is highlighted in the In This Issue feature, p. 1.

SUBMITTER: Hong A 

PROVIDER: S-EPMC6456057 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

Hong Aayoung A   Moriceau Gatien G   Sun Lu L   Lomeli Shirley S   Piva Marco M   Damoiseaux Robert R   Holmen Sheri L SL   Sharpless Norman E NE   Hugo Willy W   Lo Roger S RS  

Cancer discovery 20170918 1


Melanoma resistant to MAPK inhibitors (MAPKi) displays loss of fitness upon experimental MAPKi withdrawal and, clinically, may be resensitized to MAPKi therapy after a drug holiday. Here, we uncovered and therapeutically exploited the mechanisms of MAPKi addiction in MAPKi-resistant <i>BRAF<sup>MUT</sup></i> or <i>NRAS</i><sup>MUT</sup> melanoma. MAPKi-addiction phenotypes evident upon drug withdrawal spanned transient cell-cycle slowdown to cell-death responses, the latter of which required a r  ...[more]

Similar Datasets

2017-11-28 | GSE87326 | GEO
2022-02-17 | PXD026557 | Pride
| S-EPMC5728698 | biostudies-literature
2017-11-16 | GSE99923 | GEO
| S-EPMC6581614 | biostudies-literature
| S-EPMC4821508 | biostudies-literature
| S-EPMC7352342 | biostudies-literature
| S-EPMC6669927 | biostudies-literature
| S-EPMC4326539 | biostudies-literature
| S-EPMC7531601 | biostudies-literature